220 related articles for article (PubMed ID: 22361631)
1. Phenformin as prophylaxis and therapy in breast cancer xenografts.
Appleyard MV; Murray KE; Coates PJ; Wullschleger S; Bray SE; Kernohan NM; Fleming S; Alessi DR; Thompson AM
Br J Cancer; 2012 Mar; 106(6):1117-22. PubMed ID: 22361631
[TBL] [Abstract][Full Text] [Related]
2. Phenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK/mTOR/p70s6k and MAPK/ERK Pathways in Breast Cancer Cells.
Liu Z; Ren L; Liu C; Xia T; Zha X; Wang S
PLoS One; 2015; 10(6):e0131207. PubMed ID: 26114294
[TBL] [Abstract][Full Text] [Related]
3. Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Cai H; Everett RS; Thakker DR
Br J Pharmacol; 2019 Aug; 176(15):2724-2735. PubMed ID: 31032880
[TBL] [Abstract][Full Text] [Related]
4. Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Liu B; Fan Z; Edgerton SM; Deng XS; Alimova IN; Lind SE; Thor AD
Cell Cycle; 2009 Jul; 8(13):2031-40. PubMed ID: 19440038
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Park JH; Kim YH; Park EH; Lee SJ; Kim H; Kim A; Lee SB; Shim S; Jang H; Myung JK; Park S; Lee SJ; Kim MJ
Cancer Sci; 2019 Sep; 110(9):2834-2845. PubMed ID: 31278880
[TBL] [Abstract][Full Text] [Related]
6. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
Orecchioni S; Reggiani F; Talarico G; Mancuso P; Calleri A; Gregato G; Labanca V; Noonan DM; Dallaglio K; Albini A; Bertolini F
Int J Cancer; 2015 Mar; 136(6):E534-44. PubMed ID: 25196138
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.
Rajeshkumar NV; Yabuuchi S; Pai SG; De Oliveira E; Kamphorst JJ; Rabinowitz JD; Tejero H; Al-Shahrour F; Hidalgo M; Maitra A; Dang CV
Clin Cancer Res; 2017 Sep; 23(18):5639-5647. PubMed ID: 28611197
[No Abstract] [Full Text] [Related]
8. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
9. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Phoenix KN; Vumbaca F; Claffey KP
Breast Cancer Res Treat; 2009 Jan; 113(1):101-11. PubMed ID: 18256928
[TBL] [Abstract][Full Text] [Related]
12. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells.
Rosilio C; Lounnas N; Nebout M; Imbert V; Hagenbeek T; Spits H; Asnafi V; Pontier-Bres R; Reverso J; Michiels JF; Sahra IB; Bost F; Peyron JF
Cancer Lett; 2013 Aug; 336(1):114-26. PubMed ID: 23612073
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
14. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.
Segal ED; Yasmeen A; Beauchamp MC; Rosenblatt J; Pollak M; Gotlieb WH
Biochem Biophys Res Commun; 2011 Nov; 414(4):694-9. PubMed ID: 21986525
[TBL] [Abstract][Full Text] [Related]
15. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.
Totten SP; Im YK; Cepeda Cañedo E; Najyb O; Nguyen A; Hébert S; Ahn R; Lewis K; Lebeau B; La Selva R; Sabourin V; Martínez C; Savage P; Kuasne H; Avizonis D; Santos Martínez N; Chabot C; Aguilar-Mahecha A; Goulet ML; Dankner M; Witcher M; Petrecca K; Basik M; Pollak M; Topisirovic I; Lin R; Siegel PM; Kleinman CL; Park M; St-Pierre J; Ursini-Siegel J
Nat Commun; 2021 Jun; 12(1):3299. PubMed ID: 34083537
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
17. Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module.
Di Magno L; Manni S; Di Pastena F; Coni S; Macone A; Cairoli S; Sambucci M; Infante P; Moretti M; Petroni M; Nicoletti C; Capalbo C; De Smaele E; Di Marcotullio L; Giannini G; Battistini L; Goffredo BM; Iorio E; Agostinelli E; Maroder M; Canettieri G
Cell Rep; 2020 Feb; 30(6):1735-1752.e7. PubMed ID: 32049007
[TBL] [Abstract][Full Text] [Related]
18. Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells.
Smith JS; Colon J; Madero-Visbal R; Isley B; Konduri SD; Baker CH
Anticancer Agents Med Chem; 2010 Oct; 10(8):644-6650. PubMed ID: 21184665
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Metabolic Inhibitors in the Treatment of Colon Adenocarcinoma Patient-Derived Models.
Lee B; Lee C; Moon HM; Jo SY; Jang SJ; Suh YA
Cells; 2023 Dec; 12(24):. PubMed ID: 38132178
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
